Forscherin im Labor

Welcome to Merz

Merz is an independent international pharmaceutical company with its own research and development. Core competences are medical and aesthetic dermatology and neurological movement disorders.

In the aesthetics field, Merz offers a well-balanced range of products for minimally invasive wrinkle treatments and volume augmentation. With its brands for hair loss and scar treatment, Merz is an important player in medical dermatology.
Read more




News

  • 30. July 2014

    COMPANY ULTHERA, INC. Company`s Largest Acquisition Strengthens Aesthetics Business

    Frankfurt, Greensboro, N.C. and Mesa, A.Z. – July 29, 2014 – Merz and Ulthera, Inc. have finalized a transaction for Merz to acquire the global medical device company, officials announced today. This announcement follows gaining necessary regulatory approvals from the U.S. Trade Commission and the U.S. Department of Justice.

  • 26. June 2014

    MERZ TO ACQUIRE ULTHERA, INC., a leading energy device company in the area of non-invasive lift

    Merz and Ulthera, Inc. today announced that they have entered a definitive merger agreement, pursuant to which Merz will acquire U.S.-based medical device company Ulthera, a deal which will accelerate Merz’s growth in the aesthetics area and expand the company’s portfolio of treatment options in facial aesthetics.

  • 23. May 2014

    Beat Neukom Is the New CFO of Merz Group

    The Merz Group is expanding its management team to include yet another executive with an international background. As of July 1, 2014, Beat Neukom will be the Merz Group’s Chief Financial Officer, and therefore a member of the Merz Pharma Board.

  • 10. April 2014

    Belotero – An innovative hyaluronic acid dermal filler range by Merz Aesthetics

    Frankfurt, April 10, 2014 – Merz Aesthetics, a division of Merz Pharmaceuticals and global leader in the field of aesthetics, proudly introduces Belotero®: its range of innovative hyaluronic acid fillers, provided with and without lidocaine.

  • 15. November 2013

    The Merz Pharma Group successful after realignment

    Growth continues / Group revenue increases by 7.4 % to EUR 980.2 million / vigorous growth in foreign operations and the aesthetics business / portfolio broadened by successful acquisitions / positive trends validate corporate strategy

  • 08. November 2013

    Merz Pharma acquires Swiss aesthetic medicine specialist Anteis

    Merz Pharma today announced that it has purchased the Swiss company Anteis S.A., which is specialized in the development, manufacture and commercialization of biomedical products in the area of aesthetics. This completes a union of two companies that have been working in strong and trustworthy partnership for many years. The acquisition strengthens Merz Aesthetics’ portfolio and reinforces its market position in the field of aesthetic medicine while merging Anteis’ operations into one of the leading providers worldwide.

  • 22. October 2013

    She makes cell structures light up: Merz’ visiting professor Jennifer Lippincott-Schwartz gives an insight into the undiscovered inner of cells

    Prof. Jennifer Lippincott-Schwartz was assigned to the Friedrich Merz Foundation’s Visiting Professorship, which offers topics ranging from basic research to health care research.

  • 31. July 2013

    Merz Pharma takes over Swiss dermatology specialist Neocutis

    Merz Pharma Group (Frankfurt am Main) today announced that it has acquired the Swiss pharmaceutical company Neocutis S.A. The acquisition of the company`s cosmeceutical skin care business strengthens Merz`s market position in the field of aesthetic dermatology.

  • 13. June 2013

    Brent Hatzis-Schoch is new Head of Legal

    Brent Hatzis-Schoch will be joining Merz Pharma in Frankfurt as Chief Legal Counsel with effect from July 1. As a member of the Merz Pharma Board, Hatzis-Schoch will be responsible for Corporate Legal, Patent Affairs, Litigation Management and Compliance.

  • 08. April 2013

    Merz Pharma Group Withdraws Proposal to Acquire Obagi Medical Products

    Merz Pharma Group (“Merz” or “the Company”) today announced that it has withdrawn its non-binding proposal to acquire all of the outstanding common stock of Obagi Medical Products, Inc. (NASDAQ-GS: OMPI) (“Obagi”) for $22 per share in cash. The decision to withdraw the proposal follows the recent announcement that Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) (“Valeant”) increased its offer to acquire Obagi from $19.75 to $24.00 per share in cash, pursuant to an amendment to the Valeant and Obagi Agreement and Plan of Merger, dated March 19, 2013.

Login for Professionals



last update 31. Juli 2014, 14:22 Uhr

produced by GPM mbH

Extended search

Filter results on the following areas




Merz [Logo] Merz [Logo]

Welcome to Merz - Merz Pharma

URL: http://www.merz.com/
Stand: 23-Aug-2014, 08:47 PM
© 2014 Merz Pharma. All rights reserved.